Farglitazar
CAS: 196808-45-4
Ref. 3D-WHA80845
25mg | Nachfragen | ||
50mg | Nachfragen | ||
100mg | Nachfragen | ||
250mg | Nachfragen | ||
500mg | Nachfragen |
Produktinformation
- <span class="text-smallcaps">L</span>-Tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-
- G1 262570
- Gi 262570X
- Gi-262570
- N-(2-Benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-<span class="text-smallcaps">L</span>-tyrosine
- N-(2-Benzoylphenyl)-O-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyrosine
- N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-L-tyrosine
Farglitazar is a hydroxyl fatty acid ester that inhibits the enzyme fatty acid synthase, which plays an important role in the production of triglycerides. It has been shown to be active in vitro, but it has low potency and is not effective in vivo. Farglitazar is used for the treatment of metabolic disorders such as type 2 diabetes mellitus. It is believed that this drug works by inhibiting the synthesis of fatty acids from carbohydrates, thereby reducing hepatic glucose production. Farglitazar blocks the activation of granulosa cells and reduces testosterone levels in men because it inhibits phosphorylation of protein kinase B (PKB). The binding sites for farglitazar are steric interactions with collagen and hydrogen bond formation with water molecules.
Chemische Eigenschaften
Technische Anfrage zu: 3D-WHA80845 Farglitazar
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.